Sign in
Taking people in United StatesPhase 1

Tests VIP943 in adults with advanced CD123-positive blood cancers

Tests VIP943, a new drug, in adults with advanced leukemia or myelodysplastic syndrome.

Key facts

Who runs it
Vincerx Pharma, Inc.
Where
Birmingham, Cincinnati, Houston, Nashville, and Seattle, United StatesSee the 5 sites
Trial code
Registry title
Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
Status
Recruiting
Phase
Phase 1
People taking part
36 people, planned
Started
13 Sept 2023
Planned end
31 Dec 2025
Type of study
Interventional, 2 groups
Treatments tested
  • VIP943 (QW)
  • VIP943 (BIW)
Record updated
15 November 2024

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with advanced AML, B-ALL or high-risk MDS whose cells show CD123, and who have used up standard treatments or cannot receive them.

Age
18 years or older
Sex
All sexes can join
Disease stage
Advanced AML, B-ALL or MDS confirmed by tissue tests. At least 5% blasts (or myeloblasts in MDS) in bone marrow or blood.
Earlier treatment
Must have used all available standard therapies, or be judged unable to receive them.
Biomarker or test result
CD123 expression shown by a local laboratory.

Main reasons for not taking part

  • Known cancer spread to the central nervous system or cancer in the brain lining
  • Serious heart disease, including heart failure above NYHA Class II
  • Unstable angina or new angina within the last 6 months
  • Heart attack within the last 6 months
  • Performance status (ECOG) above 2

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • Histologically confirmed AML, B-ALL or MDS. Subjects must have exhausted all available standard therapies or be deemed ineligible for potential available therapies
  • Evidence of ≥5% bone marrow or blood blasts (acute leukemia) or ≥5% bone marrow or blood myeloblasts (MDS) to allow for assessment of drug activity
  • Evidence of CD123 expression from a local laboratory
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2

Who cannot take part

  • Clinically significant cardiac disease including congestive heart failure > New York Heart Association (NYHA) Class II), evidence for coronary artery disease (eg, unstable angina (anginal symptoms at rest) or new-onset angina (within the last 6 months or myocardial infarction within the past 6 months before first dose
  • Known central nervous system (CNS) metastases and/or carcinomatous meningitis

Where in United States

  • University of Alabama at BirminghamBirmingham, United StatesContact: Research SiteTaking people
  • University of CincinnatiCincinnati, United StatesContact: Research SiteTaking people
  • MD Anderson Cancer CenterHouston, United StatesContact: Research SiteTaking people
  • TriStar Bone Marrow TransplantNashville, United StatesContact: Research SiteTaking people
  • Fred Hutchinson Cancer CenterSeattle, United StatesContact: Research SiteTaking people

About the trial

What the trial wants to find out

Dose Escalation - Determine the maximum tolerated dose (MTD), if possible, or minimum optimal biologic dose (OBD), and evaluate the safety and tolerability of VIP943 in subjects with advanced CD123+ hematologic malignancies

The 2 groups in the trial

  • Dose Escalation of VIP943 (QW)Treatment being tested

    Subjects with AML, MDS, and B-ALL with CD123 expression will be administered VIP 943 in sequential ascending doses as a monotherapy via intravenous (IV) administration weekly (QW).

    Treatment: VIP943 (QW)

  • Dose Escalation of VIP943 (BIW)Treatment being tested

    Subjects with AML, MDS, and B-ALL with CD123 expression will be administered VIP 943 in sequential ascending doses as a monotherapy via intravenous (IV) administration twice weekly (BIW).

    Treatment: VIP943 (BIW)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
An Open-label, Multicenter Phase 1 Study to Characterize Safety, Tolerability, Preliminary Antitumor Activity, Pharmacokinetics, and Pharmacodynamics of VIP943 Monotherapy in Subjects With Advanced CD123+ Hematologic Malignancies
Plain-language title
Tests VIP943 in adults with advanced CD123-positive blood cancersGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
15 November 2024